Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week phase 2b extension study
A. Gimenez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr
Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study
M. Maurer, A. Giménez-Arnau, V. Jain, A. Reich, CE. Ortmann, P. Walsh, S. Haemmerle
Evaluating the implementation and effectiveness of an "Urticaria Care Package" to support the assessment and use of Patient Reported Outcomes in the management of Chronic Spontaneous Urticaria: An implementation science project
P. A. Laires, M. Bartezaghi, O. Bonavita, E. Peruzzi, G. Dasari, N. Janssens, V. Herrera, E. Gibbons, J. N. Hill, I. Nikolaev, S. De Geest
Low urticaria control test (UCT) scores are a significant predictor of poor response to antihistamines: analysis from worldwide real-world data (AWARE study)
A. Rajan, P. A. Laires, N. Janssens, S. Rizvi, S. Smeets, K. Weller
Comparative economic burden of chronic spontaneous urticaria, psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)
S. Gupta, M-M. Balp, S. Walsh, B. L. Balkaran, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, K. Krupsky, A. Romero, T. El-Shanawany, F. Tétart, J. Reed
Humanistic burden of chronic spontaneous urticaria relative to psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)
M-M. Balp, S. Walsh, B. L. Balkaran, S. Gupta, K. Krupsky, C. Lienhard, J. Loh, J.M. Rodriguez Barrios, A. Romero, F. Tétart, T. El-Shanawany, J. Reed
Impact of severity on the humanistic burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, United Kingdom)
S. Gupta, M-M. Balp, B. L. Balkaran, K. Krupsky, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, S. Walsh, A. Romero, F. Tétart, J. Reed, T. El-Shanawany
Prevalence and clinical profile of patients with chronic inducible urticaria in the EU5 (France, Germany, Italy, Spain, United Kingdom)
M-M. Balp, K. Krupsky, B. L. Balkaran, S. Gupta, C. Lienhard, S. Walsh, J. Loh, J. M. Rodriguez Barrios, A. Romero, F. Tétart, J. Reed, T. El-Shanawany
Comorbidity burden and healthcare resource utilization associated with non-response to H1-antihistamines alone or in combination with non-biologic treatments for chronic spontaneous urticaria
W. Soong, D. Patil, I. Pivneva, R. Bhak, J. Signorovitch, M-M. Balp, K. Freedle
Moderate to severe chronic spontaneous urticaria has a similar quality of life impact to moderate to severe plaque psoriasis: results from the data42 platform to repurpose clinical trial data
I. Nikolaev, N. Barbier, C-E. Ortmann, N. Janssens, N. Chapman-Rothe, N. Hajizadeh, O. Hsine, A. Rajan, P. A. Laires, H. Edgren
Chronic Spontaneous Urticaria: defining the pathway to successful management A panel discussion on overcoming roadblocks to CSU care, based on real life experiences
M. Maurer, E. Kocatürk and S. Savic
Live Q&A
M. Maurer, E. Kocatürk and S. Savic
2021
Ligelizumab achieves fast control of symptoms in patients with chronic spontaneous urticaria: A rolling UAS7 analysis
M. Maurer, A. M. Giménez-Arnau, W. Soong, M. Hide, J. A. Bernstein, S. Acharya, A. Barve, T. Severin
Predicting time to natural remission in chronic urticaria using random survival forest model
I. Pivneva, M-M Balp, Y. Geissbühler, A. Danyliv, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Marsland, W. Soong
Factors influencing natural remission in chronic urticaria – preliminary results from a machine learning real-world study
M-M. Balp, I. Pivneva, Y. Geissbühler, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Danyliv, W. Soong, A. Marsland
Prevalence and incidence of diagnosed chronic spontaneous/idiopathic urticaria (CSU/CIU) in the insured US population: a real-world study using claims data
Y. Geissbühler, M-M. Balp, A. Mcconnon, J. Schäl, J. Gomme, S. Pal, S. J. McKenna, P. A. Laires, W. Soong
Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab
M. Maurer, A. M. Giménez-Arnau, W. Soong, J.A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, A. Barve, T. Severin, R. Janocha
Disease control correlates with improvement of dermatology quality of life in CSU patients with angioedema treated with ligelizumab
A. M. Giménez-Arnau, M. Maurer, W. Soong, J. A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, P. Gupta, A. Barve, T. Severin, R. Janocha, M. Balp
LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin
M. Kaul, J. Storim, P. End, M. Cabanski, A. Jakab, C. Schuhler, E. Funhoff, F. Schaefer, E. Dimanova, M. Kistowska, A. Kinhikar, A. Maiolica, A. Sinn, R. Fuhr, B. Cenni
Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled, phase 2b dose-finding study
M. Maurer, A. Giménez -Arnau, G. Sussman, J. Loeffler, A. Barve, T. Severin, R. Janocha